JP2011503019A - 薬学的使用のための新規のニュールツリン複合体 - Google Patents
薬学的使用のための新規のニュールツリン複合体 Download PDFInfo
- Publication number
- JP2011503019A JP2011503019A JP2010532485A JP2010532485A JP2011503019A JP 2011503019 A JP2011503019 A JP 2011503019A JP 2010532485 A JP2010532485 A JP 2010532485A JP 2010532485 A JP2010532485 A JP 2010532485A JP 2011503019 A JP2011503019 A JP 2011503019A
- Authority
- JP
- Japan
- Prior art keywords
- neurturin
- protein product
- polyethylene glycol
- amino acid
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000001839 Neurturin Human genes 0.000 title claims abstract description 259
- 108010015406 Neurturin Proteins 0.000 title claims abstract description 259
- 150000003077 polyols Chemical class 0.000 claims abstract description 24
- 239000004480 active ingredient Substances 0.000 claims abstract description 21
- 230000001965 increasing effect Effects 0.000 claims abstract description 12
- 229920001223 polyethylene glycol Polymers 0.000 claims description 82
- 150000001413 amino acids Chemical class 0.000 claims description 44
- 101001108441 Homo sapiens Neurturin Proteins 0.000 claims description 39
- 102000052667 human NRTN Human genes 0.000 claims description 36
- 235000001014 amino acid Nutrition 0.000 claims description 34
- 239000000203 mixture Substances 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 31
- 239000002202 Polyethylene glycol Substances 0.000 claims description 27
- 239000012634 fragment Substances 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 238000011282 treatment Methods 0.000 claims description 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 18
- 230000000694 effects Effects 0.000 claims description 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 13
- 229920001184 polypeptide Polymers 0.000 claims description 12
- 239000002671 adjuvant Substances 0.000 claims description 11
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 11
- 239000003085 diluting agent Substances 0.000 claims description 10
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 9
- 125000000539 amino acid group Chemical group 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 8
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims description 7
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 6
- 235000013922 glutamic acid Nutrition 0.000 claims description 6
- 239000004220 glutamic acid Substances 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 6
- 208000016222 Pancreatic disease Diseases 0.000 claims description 5
- 230000002378 acidificating effect Effects 0.000 claims description 5
- 208000001921 latent autoimmune diabetes in adults Diseases 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 241000282412 Homo Species 0.000 claims description 3
- 125000003827 glycol group Chemical group 0.000 claims description 3
- 238000001802 infusion Methods 0.000 claims description 3
- 238000010253 intravenous injection Methods 0.000 claims description 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 3
- 230000007935 neutral effect Effects 0.000 claims description 3
- 238000010254 subcutaneous injection Methods 0.000 claims description 3
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 229920001515 polyalkylene glycol Polymers 0.000 claims 1
- 229920005862 polyol Polymers 0.000 abstract description 9
- 108090000623 proteins and genes Proteins 0.000 description 45
- 235000018102 proteins Nutrition 0.000 description 41
- 102000004169 proteins and genes Human genes 0.000 description 41
- 239000000047 product Substances 0.000 description 40
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 28
- 230000006320 pegylation Effects 0.000 description 26
- 230000004071 biological effect Effects 0.000 description 21
- 210000002966 serum Anatomy 0.000 description 19
- 238000006467 substitution reaction Methods 0.000 description 19
- 102000004877 Insulin Human genes 0.000 description 16
- 108090001061 Insulin Proteins 0.000 description 16
- 229940125396 insulin Drugs 0.000 description 16
- 238000003556 assay Methods 0.000 description 13
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 229920000642 polymer Polymers 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 239000004475 Arginine Substances 0.000 description 9
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 9
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 9
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 9
- 239000004472 Lysine Substances 0.000 description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 108700008625 Reporter Genes Proteins 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 7
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical class OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 7
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 210000000130 stem cell Anatomy 0.000 description 7
- 108700010070 Codon Usage Proteins 0.000 description 6
- 108010074860 Factor Xa Proteins 0.000 description 6
- 108060001084 Luciferase Proteins 0.000 description 6
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 6
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 229920001577 copolymer Polymers 0.000 description 6
- -1 dextrin-2-sulfate Polymers 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 230000008929 regeneration Effects 0.000 description 6
- 238000011069 regeneration method Methods 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 239000005089 Luciferase Substances 0.000 description 5
- 102220639883 Lysine-specific demethylase RSBN1L_R63E_mutation Human genes 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 238000004020 luminiscence type Methods 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000000710 homodimer Substances 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 238000001426 native polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 239000008177 pharmaceutical agent Substances 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 229920000447 polyanionic polymer Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 241000894007 species Species 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- 102220575588 40S ribosomal protein S16_R65E_mutation Human genes 0.000 description 3
- 102220497110 5-hydroxytryptamine receptor 3B_R54E_mutation Human genes 0.000 description 3
- 102220626504 Arrestin domain-containing protein 3_R52E_mutation Human genes 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 238000012286 ELISA Assay Methods 0.000 description 3
- 102220498069 Electron transfer flavoprotein subunit beta_R56E_mutation Human genes 0.000 description 3
- 102220498066 Electron transfer flavoprotein subunit beta_R60E_mutation Human genes 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 102220527183 Immunoglobulin heavy joining 1_R51E_mutation Human genes 0.000 description 3
- 102220465475 Insulin-like growth factor II_R58E_mutation Human genes 0.000 description 3
- 102220465474 Insulin-like growth factor II_R61E_mutation Human genes 0.000 description 3
- 102220639790 Lysine-specific demethylase RSBN1L_R57Q_mutation Human genes 0.000 description 3
- 102000043136 MAP kinase family Human genes 0.000 description 3
- 108091054455 MAP kinase family Proteins 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 108700025832 Serum Response Element Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 238000007385 chemical modification Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 238000000099 in vitro assay Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000003055 low molecular weight heparin Substances 0.000 description 3
- 229940127215 low-molecular weight heparin Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 3
- 229920001451 polypropylene glycol Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000010532 solid phase synthesis reaction Methods 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
- 102220497114 5-hydroxytryptamine receptor 3B_R54K_mutation Human genes 0.000 description 2
- 102220502354 Alkaline ceramidase 1_R57K_mutation Human genes 0.000 description 2
- 102220594998 Ankyrin repeat and SOCS box protein 8_R60K_mutation Human genes 0.000 description 2
- CJLHTKGWEUGORV-UHFFFAOYSA-N Artemin Chemical compound C1CC2(C)C(O)CCC(=C)C2(O)C2C1C(C)C(=O)O2 CJLHTKGWEUGORV-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 2
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 2
- 102220531201 Dyslexia-associated protein KIAA0319-like protein_R52K_mutation Human genes 0.000 description 2
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 102220527182 Immunoglobulin heavy joining 1_R51K_mutation Human genes 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 241000289371 Ornithorhynchus anatinus Species 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 102220507521 V-type proton ATPase subunit F_R61K_mutation Human genes 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 150000003862 amino acid derivatives Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 150000001483 arginine derivatives Chemical class 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 102220358488 c.167G>A Human genes 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 229940059329 chondroitin sulfate Drugs 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229920001427 mPEG Polymers 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 238000009163 protein therapy Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 102220190317 rs200951126 Human genes 0.000 description 2
- 102220214050 rs774009993 Human genes 0.000 description 2
- 235000004400 serine Nutrition 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 description 1
- WNPNUJDICWIQGG-UHFFFAOYSA-N 1-amino-2,2-dimethyl-3-oxopent-4-ene-1-sulfonic acid Chemical compound OS(=O)(=O)C(N)C(C)(C)C(=O)C=C WNPNUJDICWIQGG-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 102100026376 Artemin Human genes 0.000 description 1
- 101710205806 Artemin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 229920000855 Fucoidan Polymers 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102100038224 Kremen protein 2 Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920001543 Laminarin Polymers 0.000 description 1
- 239000005717 Laminarin Substances 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000736256 Monodelphis Species 0.000 description 1
- 108090000143 Mouse Proteins Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100454122 Mus musculus Kremen1 gene Proteins 0.000 description 1
- 101001108442 Mus musculus Neurturin Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 101800000933 Non-structural protein 10 Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108091006006 PEGylated Proteins Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000006470 autoimmune attack Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000004182 chemical digestion Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000013267 controlled drug release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 229960004969 dalteparin Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 229960000610 enoxaparin Drugs 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- VEWLDLAARDMXSB-UHFFFAOYSA-N ethenyl sulfate;hydron Chemical compound OS(=O)(=O)OC=C VEWLDLAARDMXSB-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 229940087051 fragmin Drugs 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000004545 gene duplication Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000002628 heparin derivative Substances 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- RWYGQIQKHRMKFH-UHFFFAOYSA-N naphthalene;sulfuric acid Chemical compound OS(O)(=O)=O.C1=CC=CC2=CC=CC=C21 RWYGQIQKHRMKFH-UHFFFAOYSA-N 0.000 description 1
- 230000009707 neogenesis Effects 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000002571 pancreatic alpha cell Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 229920013730 reactive polymer Polymers 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- HGBOYTHUEUWSSQ-UHFFFAOYSA-N valeric aldehyde Natural products CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
et al., 2003, Nat Rev Immunol. 3: 123-132;Homann et
al., Immunity. 2002, 3: 403-415)。しかしながら、ヒトβ細胞の相対的に遅い再生のため、このような治療は、それらが、β細胞再生を刺激し得る治療と組合される場合、よりうまくいく。
(発明の詳細な説明)
Nieforth) Dekker, New York, 1997, pp 209)、硫酸ポリグリセリン(Turk,
H., Haag, R., Alban, S. Bioconjugate Chem. 2004, 15, 162)、ポリ硫酸ペントサン(PPS)およびその誘導体、例えばラクトース修飾ポリ硫酸ペントサン、分別PPS/低分子量PPS、フコイダン、あるいはその誘導体または組合せから選択される。
(1992(249-304))も参照)。
(1997) 218-238に従って実施され得る。選択的N末端PEG化は、N−PEG化アミノ酸誘導体をペプチド鎖のN末端アミノ酸と結合することにより、固相合成中に達成される。側鎖PEG化は、N−PEG化アミノ酸誘導体を成長中の鎖と結合することにより、固相合成中に実施される。併合N末端および側鎖PEG化は、固相合成内で上記のように、またはアミノ脱保護化ペプチドに活性化PEG試薬を適用することにより液相合成によって、プロセシングされる。
ポリエチレングリコール基(PEG)を、PEG化と呼ばれるプロセスによりニュールツリンと共役させた。この技術は治療用タンパク質の修飾のために広範に用いられ、当該手順は当業者によく知られている。本発明においては、単一PEG分子を、ホモ二量体の2つのサブユニットのうちの1つのN末端アミノ酸と連結することにより、モノPEG化ニュールツリン複合体を製造した。結合PEGのサイズおよび構造が異なり、ならびにPEGをタンパク質と共役させる製造方法が異なるモノPEG化ニュールツリンの2つの異なる複合体を製造した。約5kDaの線状PEG試薬(mPEG−スクシニミジルスクシネート;NOF, Japan)を用いて、本明細書中で「モノ−mPEG−NHS−ニュールツリン」として開示される複合体を製造した。このいわゆる「NHS法」は、可溶性タンパク質のPEG化のために最も一般的に用いられる方法である。さらに、線状5kDaポリエチレングリコールブチルアルデヒド(Nektar、082M0H01)を用いて、「モノ−mPEG−CHO−ニュールツリン」として開示される複合体を生成した。特定実験条件下で、NHSエステルまたはアルデヒドは、タンパク質およびペプチドの遊離アミノ基と効率的に反応する。「モノ−CES0310−ニュールツリン」として開示されるさらに別の複合体では、ニュールツリンホモ二量体の1つの鎖のN末端アミノ酸を、従来技術で既知のPEG化法を用いて、約5kDaの6腕分枝鎖PEGと共役させた(例えばDE2005 100 04 157.0、EP 1 631 545 A2;W04/108634;WO07/025763;CA2528667(これらに限定されない)参照)。ニュールツリンはリシン残基を含有せず、したがって、上記のPEG化反応は、主に、ニュールツリンホモ二量体のN末端アミノ酸の反応性アミノ基を介して、N末端PEG化をもたらすと予測される。当業者に既知の標準生化学的方法を用いて、PEG化産物の質(サイズおよび純度)を確証した。
実施例2−PEG化ニュールツリン複合体またはその変異体の生物学的活性
実施例3−PEG化ニュールツリン複合体またはその変異体の生物学的利用能の改良
実施例4−ニュールツリン変異体
R51E、R52E、R54E、R56E、R57E、R58E、R60E、R61E、R63EまたはR65E(成熟ヒトニュールツリンペプチドの配列に従って位置に番号を付す。GenBank寄託番号NP_004549、成熟ペプチドaa 96〜197。この配列は図3にも示されている;R:アルギニン;E:グルタミン酸)を導入するミスマッチプライマーを用いてPCRベースの突然変異誘発により、付加的N末端真核生物分泌シグナルペプチドを伴う成熟ヒトニュールツリンのコード配列を修飾した。
Kiuchi K. Heparin facilitates glial cell line-derived neurotrophic factor
signal transduction. Neuroreport. 2002 Oct 28; 13(15): 1913-6;Tanaka M, Xiao H, Hirata Y, Kiuchi K. A rapid assay for glial cell
line-derived neurotrophic factor and neurturin based on transfection of cells
with tyrosine hydroxylase promoter-luciferase construct. Brain Res Brain Res
Protoc. 2003 May; 11(2):119-22)による、ヒトTGW神経芽細胞腫細胞株中で安定的に発現されるニュールツリンによるチロシンヒドロキシラーゼ(TH)レポーター遺伝子構築物の誘導を示す実験に基づいている。要するに、チロシンヒドロキシラーゼ(TH)レポーター遺伝子構築物を過剰発現するTGW細胞を、ニュールツリン含有試料で処理して、ニュールツリンシグナル伝達によるMAPK経路の誘導をもたらす。レポーター遺伝子構築物は、反復血清応答素子(SRE)の制御下でルシフェラーゼ遺伝子を含有する。ルシフェラーゼの発現は、MAPK経路活性化に依っている。96ウエルプレート中で検定を実行する。ニュールツリン媒介性ルシフェラーゼ発現をルシフェリンの付加により測定し、ルミネッセンス読取装置で解析する。
domestica)およびニワトリ(Gallus gallus)のヒトニュールツリン相同体中に存在する、ということを示す。さらにまた、位置52、57、58および61でのアルギニン残基の天然変異体は、異なるニュールツリン相同体中に存在する(図6参照)。
・Kr:ヒトコドン使用のために最適化される細胞質分泌に関するマウスクリングル含有膜貫通タンパク質2、アミノ酸1〜26、シグナルペプチド(GenBank寄託番号NP_082692)のDNA配列(アミノ酸配列:MGTPHLQGFLLLFPLLLRLHGASAGS;配列番号2)。
・G3:ヒトコドン使用のために最適化されるグリシンスペーサーのDNA配列(アミノ酸配列:GGG;配列番号3)。
H6:ヒトコドン使用のために最適化される精製目的のための6−ヒスチジンタグのDNA配列(アミノ酸配列:HHHHHH;配列番号4)。
Xa:ヒトコドン使用のために最適化される因子Xaプロテアーゼ認識部位のDNA配列(アミノ酸配列;IEGR;配列番号5)。因子Xaプロテアーゼはアルギニンの後でC末端を切断する。
rhニュールツリン:ヒトコドン使用のために最適化される成熟組換えヒトニュールツリンのDNA配列(アミノ酸配列:ARLGARPCGLRELEVRVSELGLGYASDETVLFRYCAGACEAAARVYDLGLRRLRQRRRLRRERVRAQPCCRPTAYEDEVSFLDAHSRYHTVHELSARECACV;配列番号6)。位置51、52、54、56、57、58、60、61、63または65の単一アルギニンコドンは、それぞれのニュールツリン変異体発現構築物中のリシンコドンAAGにより置き換えられる。
実施例5−ニュールツリン変異体のPEG化
vivoで検定する。基線での、ならびに投与後0.25、0.5、1、1.5、2、3、4、6および8時間目に、ニュールツリンELISAにより、血漿ニュールツリン濃度を確定する。
実施例6−PEG化ニュールツリンの免疫原性能力
Claims (33)
- ヒトニュールツリンタンパク質産物またはその生物学的活性断片と共有結合されるポリオール部分を含むニュールツリン複合体。
- 配列番号1で記述されるアミノ酸配列によりコードされるポリペプチド、あるいはその相同体、オルソログ、変異体、類似体、誘導体、生物学的活性断片または生物学的活性突然変異体を含む請求項1記載のニュールツリン複合体。
- 前記ポリオール部分がポリエチレングリコール部分である請求項1または2記載のニュールツリン複合体。
- 前記ポリオール部分が一本鎖ポリオール部分である請求項1〜3のいずれか一項に記載のニュールツリン複合体。
- 前記ポリオール部分が分枝鎖ポリオール部分である請求項1〜3のいずれか一項に記載のニュールツリン複合体。
- 前記ポリオール部分がポリアルキレングリコール部分である請求項1〜3のいずれか一項に記載のニュールツリン複合体。
- ネイティブヒトニュールツリンと同一のまたはそれより高いin vivoニュールツリン活性を有する請求項1〜6のいずれか一項に記載のニュールツリン複合体。
- ヒトニュールツリンと比較して少なくとも1つのアミノ酸変化を有する請求項1〜7のいずれか一項に記載のニュールツリン複合体。
- 前記アミノ酸変化が成熟ヒトニュールツリンのアミノ酸47〜69、好ましくは51〜65の間である請求項8記載のニュールツリン複合体。
- アルギニン残基51、52、54、56、57、58、60、61または65のうちの少なくとも1つが欠失されるかまたは置換される請求項8または9のいずれか一項に記載のニュールツリン複合体。
- 少なくとも1つのアルギニン残基が中性または酸性アミノ酸残基、例えばグルタミン酸により置換される請求項10記載のニュールツリン複合体。
- 少なくとも1つのリシン残基が導入される請求項8〜10のいずれか一項に記載のニュールツリン複合体。
- 活性成分としての少なくとも1つのポリエチレングリコール分子と共役する少なくとも1つのニュールツリンタンパク質産物および/またはその生物学的活性断片を製薬上許容可能な担体、希釈剤および/またはアジュバントと一緒に含む製剤組成物。
- 前記ニュールツリンタンパク質産物がヒトニュールツリンタンパク質産物またはその生物学的活性断片である請求項13記載の組成物。
- 前記修飾ニュールツリンタンパク質産物がモノ−PEG化され、単一ポリエチレングリコール分子鎖を含む請求項13または14のいずれか一項に記載の組成物。
- 前記修飾ニュールツリンタンパク質産物がオリゴ−またはポリ−PEG化され、2、3、4つまたは数個のポリエチレングリコール分子鎖を含む請求項13または14のいずれか一項に記載の組成物。
- 前記修飾ニュールツリンタンパク質産物が少なくとも1つの線状ポリエチレングリコール分子鎖を含む請求項13〜16のいずれか一項に記載の組成物。
- 前記修飾ニュールツリンタンパク質産物が少なくとも1つの分枝鎖ポリエチレングリコール分子鎖を含む請求項13〜16のいずれか一項に記載の組成物。
- 前記ポリエチレングリコール分子が100〜10000Daの、好ましくは200〜8000Daの、最も好ましくは1000〜7000Daの平均分子量を有する請求項13〜18のいずれか一項に記載の組成物。
- 前記ポリエチレングリコール分子が前記修飾ニュールツリンタンパク質産物のN末端アミノ酸に連結される請求項13〜19のいずれか一項に記載の組成物。
- 前記ポリエチレングリコール分子がアシルまたはアルキル結合を介して前記修飾ニュールツリンタンパク質産物に連結される請求項13〜20のいずれか一項に記載の組成物。
- 前記ポリエチレングリコール分子がOH−、OCH3−またはOEt−基により終結される請求項13〜21のいずれか一項に記載の組成物。
- 非修飾対照ニュールツリンタンパク質産物と比較して活性成分の生物学的利用能増大を示す請求項13〜22のいずれか一項に記載の組成物。
- 前記修飾ニュールツリンタンパク質が活性成分の生物学的利用能の少なくとも2倍の、好ましくは少なくとも5倍の、さらに好ましくは少なくとも10倍の増大を提供する量で存在する請求項13〜23のいずれか一項に記載の組成物。
- 注射または注入のための請求項13〜24のいずれか一項に記載の組成物。
- 皮下または静脈内注射のための請求項25記載の組成物。
- 膵臓または神経変性障害の予防または治療のための請求項13〜26のいずれか一項に記載の組成物。
- I型真性糖尿病、LADAおよびII型真性糖尿病の予防または治療のための請求項27記載の組成物。
- 哺乳類、特にヒトへの投与のための請求項13〜28のいずれか一項に記載の組成物。
- 野生型ヒトニュールツリンと比較して少なくとも1つの、例えば1、2、3または4つのアミノ酸変化を含むヒトニュールツリンの変異体。
- アミノ酸変化が請求項9〜12に定義されたものと同じである請求項30記載のヒトニュールツリンの変異体。
- 活性成分としての少なくとも1つのポリエチレングリコール分子と共役する少なくとも1つの修飾ニュールツリンタンパク質産物またはその生物学的活性断片を、製薬上許容可能な担体、希釈剤および/またはアジュバントと一緒に含む製剤組成物をそれを必要とする被験者に投与するための方法。
- 活性成分としての少なくとも1つのポリエチレングリコール分子と共役する少なくとも1つの修飾ニュールツリンタンパク質産物またはその生物学的活性断片を、低分子量物質と一緒に、製薬上許容可能な担体、希釈剤および/またはアジュバントと一緒に含む製剤組成物をそれを必要とする被験者に投与するための方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07021493 | 2007-11-05 | ||
PCT/EP2008/009320 WO2009059755A2 (en) | 2007-11-05 | 2008-11-05 | Novel neurturin conjugates for pharmaceutical use |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014182466A Division JP2015057384A (ja) | 2007-11-05 | 2014-09-08 | 薬学的使用のための新規のニュールツリン複合体 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011503019A true JP2011503019A (ja) | 2011-01-27 |
JP2011503019A5 JP2011503019A5 (ja) | 2011-12-22 |
Family
ID=40521395
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010532485A Pending JP2011503019A (ja) | 2007-11-05 | 2008-11-05 | 薬学的使用のための新規のニュールツリン複合体 |
JP2014182466A Pending JP2015057384A (ja) | 2007-11-05 | 2014-09-08 | 薬学的使用のための新規のニュールツリン複合体 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014182466A Pending JP2015057384A (ja) | 2007-11-05 | 2014-09-08 | 薬学的使用のための新規のニュールツリン複合体 |
Country Status (17)
Country | Link |
---|---|
US (3) | US9029323B2 (ja) |
EP (1) | EP2217282A2 (ja) |
JP (2) | JP2011503019A (ja) |
KR (2) | KR20100098619A (ja) |
CN (2) | CN104288775A (ja) |
AU (1) | AU2008324426B2 (ja) |
BR (1) | BRPI0819220A2 (ja) |
CA (1) | CA2742839A1 (ja) |
CO (1) | CO6280503A2 (ja) |
CR (1) | CR11406A (ja) |
EA (1) | EA201070484A1 (ja) |
IL (1) | IL205290A (ja) |
MX (1) | MX2010004899A (ja) |
NZ (1) | NZ585262A (ja) |
SG (1) | SG185946A1 (ja) |
WO (1) | WO2009059755A2 (ja) |
ZA (1) | ZA201003227B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012150707A1 (ja) * | 2011-05-02 | 2012-11-08 | 国立大学法人熊本大学 | 幹細胞からインスリン産生細胞への分化誘導を促進する低分子化合物および該化合物を用いた幹細胞からインスリン産生細胞への分化誘導方法 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050222070A1 (en) | 2002-05-29 | 2005-10-06 | Develogen Aktiengesellschaft Fuer Entwicklungsbiologische Forschung | Pancreas-specific proteins |
PL1694354T3 (pl) | 2003-11-27 | 2009-12-31 | Develogen Ag | Sposób zapobiegania i leczenia cukrzycy za pomocą neurturyny |
US9127083B2 (en) | 2009-10-30 | 2015-09-08 | Ntf Therapeutics, Inc. | Neurturin molecules |
US8445432B2 (en) | 2009-10-30 | 2013-05-21 | Ntf Therapeutics Inc | Neurturin molecules |
BR112012009801A8 (pt) * | 2009-10-30 | 2016-08-30 | Cns Therapeutics Inc | Polipeptídeo neurturina e variante de neurturina |
US8742677B2 (en) * | 2010-01-11 | 2014-06-03 | System General Corp. | LED drive circuit with a programmable input for LED lighting |
CN102453725B (zh) * | 2010-11-02 | 2014-06-11 | 杭州纽龙生物科技有限公司 | 一种重组载体、包含该重组载体的重组菌株及制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11512928A (ja) * | 1995-08-28 | 1999-11-09 | ワシントン ユニヴァーシティー | ニュールツリンおよび関連成長因子 |
JP2001525316A (ja) * | 1997-07-30 | 2001-12-11 | アムジエン・インコーポレーテツド | ニュールツリンタンパク質産物を使用する難聴の予防および治療方法 |
JP2007509109A (ja) * | 2003-10-20 | 2007-04-12 | エヌエスジーン・アクティーゼルスカブ | パーキンソン病のインビボ遺伝子治療 |
JP2007512290A (ja) * | 2003-11-27 | 2007-05-17 | デヴェロゲン アクチエンゲゼルシャフト | ニュールツリンを用いる糖尿病の予防と治療方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU778998B2 (en) * | 1998-09-22 | 2004-12-23 | University Of Maryland At Baltimore | Cystine knot growth factor mutants |
US7442370B2 (en) * | 2001-02-01 | 2008-10-28 | Biogen Idec Ma Inc. | Polymer conjugates of mutated neublastin |
US20050222070A1 (en) * | 2002-05-29 | 2005-10-06 | Develogen Aktiengesellschaft Fuer Entwicklungsbiologische Forschung | Pancreas-specific proteins |
JP2005527614A (ja) | 2002-05-29 | 2005-09-15 | デヴェロゲン アクチエンゲゼルシャフト フュア エントヴィックルングスビオローギッシェ フォルシュング | 膵臓特異性タンパク質 |
EP1872790A1 (en) * | 2006-06-26 | 2008-01-02 | DeveloGen Aktiengesellschaft | New formulation for increasing bioavailability of neurturin |
-
2008
- 2008-11-05 JP JP2010532485A patent/JP2011503019A/ja active Pending
- 2008-11-05 EA EA201070484A patent/EA201070484A1/ru unknown
- 2008-11-05 MX MX2010004899A patent/MX2010004899A/es active IP Right Grant
- 2008-11-05 WO PCT/EP2008/009320 patent/WO2009059755A2/en active Application Filing
- 2008-11-05 AU AU2008324426A patent/AU2008324426B2/en not_active Ceased
- 2008-11-05 SG SG2012081220A patent/SG185946A1/en unknown
- 2008-11-05 KR KR1020107012303A patent/KR20100098619A/ko not_active Application Discontinuation
- 2008-11-05 KR KR1020157034049A patent/KR20150139982A/ko not_active Application Discontinuation
- 2008-11-05 NZ NZ585262A patent/NZ585262A/en not_active IP Right Cessation
- 2008-11-05 EP EP08848146A patent/EP2217282A2/en not_active Withdrawn
- 2008-11-05 BR BRPI0819220-0A patent/BRPI0819220A2/pt not_active IP Right Cessation
- 2008-11-05 CN CN201410282849.2A patent/CN104288775A/zh active Pending
- 2008-11-05 CN CN200880114325.5A patent/CN101848735B/zh not_active Expired - Fee Related
- 2008-11-05 CA CA2742839A patent/CA2742839A1/en not_active Abandoned
-
2010
- 2010-04-22 IL IL205290A patent/IL205290A/en not_active IP Right Cessation
- 2010-04-30 CR CR11406A patent/CR11406A/es unknown
- 2010-05-05 US US12/774,235 patent/US9029323B2/en not_active Expired - Fee Related
- 2010-05-07 ZA ZA2010/03227A patent/ZA201003227B/en unknown
- 2010-06-03 CO CO10067268A patent/CO6280503A2/es not_active Application Discontinuation
-
2013
- 2013-02-01 US US13/757,289 patent/US20130231283A1/en not_active Abandoned
-
2014
- 2014-09-08 JP JP2014182466A patent/JP2015057384A/ja active Pending
-
2015
- 2015-04-08 US US14/681,414 patent/US20160060317A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11512928A (ja) * | 1995-08-28 | 1999-11-09 | ワシントン ユニヴァーシティー | ニュールツリンおよび関連成長因子 |
JP2001525316A (ja) * | 1997-07-30 | 2001-12-11 | アムジエン・インコーポレーテツド | ニュールツリンタンパク質産物を使用する難聴の予防および治療方法 |
JP2007509109A (ja) * | 2003-10-20 | 2007-04-12 | エヌエスジーン・アクティーゼルスカブ | パーキンソン病のインビボ遺伝子治療 |
JP2007512290A (ja) * | 2003-11-27 | 2007-05-17 | デヴェロゲン アクチエンゲゼルシャフト | ニュールツリンを用いる糖尿病の予防と治療方法 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012150707A1 (ja) * | 2011-05-02 | 2012-11-08 | 国立大学法人熊本大学 | 幹細胞からインスリン産生細胞への分化誘導を促進する低分子化合物および該化合物を用いた幹細胞からインスリン産生細胞への分化誘導方法 |
Also Published As
Publication number | Publication date |
---|---|
IL205290A0 (en) | 2010-12-30 |
IL205290A (en) | 2014-01-30 |
CN101848735B (zh) | 2014-07-23 |
AU2008324426B2 (en) | 2014-03-27 |
BRPI0819220A2 (pt) | 2019-02-26 |
KR20100098619A (ko) | 2010-09-08 |
WO2009059755A2 (en) | 2009-05-14 |
NZ585262A (en) | 2012-06-29 |
US20130231283A1 (en) | 2013-09-05 |
MX2010004899A (es) | 2010-09-07 |
CA2742839A1 (en) | 2009-05-14 |
US20110003741A1 (en) | 2011-01-06 |
CN104288775A (zh) | 2015-01-21 |
AU2008324426A1 (en) | 2009-05-14 |
KR20150139982A (ko) | 2015-12-14 |
SG185946A1 (en) | 2012-12-28 |
CR11406A (es) | 2010-10-25 |
CO6280503A2 (es) | 2011-05-20 |
EP2217282A2 (en) | 2010-08-18 |
WO2009059755A3 (en) | 2009-09-24 |
CN101848735A (zh) | 2010-09-29 |
US20160060317A1 (en) | 2016-03-03 |
JP2015057384A (ja) | 2015-03-26 |
ZA201003227B (en) | 2011-03-30 |
EA201070484A1 (ru) | 2011-04-29 |
US9029323B2 (en) | 2015-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2015057384A (ja) | 薬学的使用のための新規のニュールツリン複合体 | |
KR101011081B1 (ko) | Peg화된 glp-1 화합물 | |
IL137858A (en) | Modified ciliary neurotrophic factor, method of making it and methods of use thereof | |
CN101870728A (zh) | 新型Exendin变体及其缀合物 | |
EP3539570B1 (en) | Pegylated endostatin analogue and application thereof | |
US20080214440A1 (en) | Vasoactive intestinal polypeptide compositions | |
KR102569658B1 (ko) | 컨쥬게이트 c1 에스테라제 억제제 및 그의 용도 | |
JP2017205120A (ja) | コリンエステラーゼ部分とポリマーとのコンジュゲート | |
CN115243725A (zh) | Fgf-21缀合物配制品 | |
US20090170775A1 (en) | Vasoactive intestinal polypeptide compositions | |
CN104447981B (zh) | 端羟基聚乙二醇化的人胰岛素及其类似物的偶联物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111101 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20111101 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111209 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130709 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131009 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140508 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140908 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150320 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20150320 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20150320 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150617 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20150617 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20150622 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20150717 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160229 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160310 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160426 |